CGON Stock Analysis: Buy, Sell, or Hold?
CGON - CG Oncology, Inc. Common stock
$63.96
-0.66 (-1.02%)
▼
5d:
-1.54%
30d:
+8.78%
90d:
+60.54%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
CGON is down 7.4% this week, but smart money is accumulating calls. Top strike: $90 2026-06-18 with 10,471 OI. Call ratio: 100% View Scanner →
Strength: 8.7/10
Get Alerted When CGON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CGON shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CGON shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CGON is currently trading at $63.96, which is considered slightly high relative to its 30-day fair value range of $58.71 to $65.61.
Technical Outlook: Technically, CGON is in a strong uptrend. The price is currently testing key support at $62.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $83.29 (+30.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CGON is in a strong uptrend. The price is currently testing key support at $62.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $83.29 (+30.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$58.71 -
$65.61
Company Quality Score
56/100
(HOLD)
Options IV Signal
14th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 14th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.2% below Wall St target ($83.29)
Fair Price Analysis
30-Day Fair Range
$58.71 -
$65.61
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$7.95
(12.4%)
Support & Resistance Levels
Support Level
$62.80
Resistance Level
$69.35
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-32.10
Wall Street Target
$83.29
(+30.2%)
Revenue Growth (YoY)
409.2%
Share & Embed Analysis
Last updated: March 30, 2026 6:36 PM ET
Data refreshes hourly during market hours. Next update: 7:36 PM
Data refreshes hourly during market hours. Next update: 7:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
James Mulay
SELL
1964 shares
2026-03-16
James Mulay
SELL
11145 shares
2026-01-09
Leonard E Post
SELL
1000 shares
2025-11-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 51 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 50 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 44 HOLD |
